Mary E. Wadlinger Receives Stock Award at Lava Therapeutics Nv (LVTX) — SEC Form 4, Feb 19, 2025
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Filing Lag
3 business days
late vs 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Mary E. Wadlinger CIK 0001814695 |
Director
|
Mary E. Wadlinger at Lava Therapeutics Nv
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at Lava Therapeutics Nv
| 2025-11-17 | - | — | View |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares (Right to Buy)F1 | $0.93 | 2025-02-13 | A - Award/Grant | 33,390 A | $0.00 | 2035-02-12 | 33,390 Common Shares | Direct |
Footnotes (1)
- F1
- 100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date. Show more
Related filings at Lava Therapeutics Nv
Institutional Holders
13F holders · Sep 30, 2025
20
institutional managers reporting a position
Largest by reported value
- Shay Capital Llc $3.98M
- Redmile Group, Llc $3.24M
- Bml Capital Management, Llc $3.07M
5%+ Holders · 13D/G
3 filers
Other insiders at Lava Therapeutics Nv
GET /v1/forms/4/0001415889-25-004531
API docs
View Original SEC Filing